{"id":55657,"date":"2023-04-11T00:04:12","date_gmt":"2023-04-10T22:04:12","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/cutera-regains-compliance-with-nasdaq-listing-rules\/"},"modified":"2023-04-11T00:04:12","modified_gmt":"2023-04-10T22:04:12","slug":"cutera-regains-compliance-with-nasdaq-listing-rules","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/cutera-regains-compliance-with-nasdaq-listing-rules\/","title":{"rendered":"Cutera Regains Compliance with Nasdaq Listing Rules"},"content":{"rendered":"
\n

BRISBANE, Calif.–(BUSINESS WIRE)–Cutera, Inc. (Nasdaq: CUTR<\/a>) (\u201cCutera\u201d or the \u201cCompany\u201d), a leading provider of aesthetic and dermatology solutions, announced today that it received a notice (the \u201cNotice\u201d) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (\u201cNasdaq\u201d) that based on the Company\u2019s April 7, 2023 filing of its Form 10-K for the period ended December 31, 2022 (\u201cForm 10-K\u201d), Nasdaq has determined that the Company is now in compliance with the periodic filing requirement of Nasdaq Listing Rule 5250(c)(1). As previously announced, the Company received a notification letter from the Nasdaq that it was not in compliance with Nasdaq Listing Rule 5250(c)(1) due to the delayed filing of its Form 10-K. The Company is now in compliance with all Nasdaq Listing Rules.<\/p>\n

\nThe Company\u2019s Form 10-K did not include any restatements of previously issued financial statements. No additional material weaknesses in the Company\u2019s internal control over financial reporting were disclosed in the Form 10-K beyond those previously disclosed by the Company in the amended Form 12b-25 filed by the Company on March 16, 2023.<\/p>\n

\nAbout Cutera, Inc.<\/b><\/p>\n

\nBrisbane, California-based Cutera is a leading provider of aesthetic and dermatology solutions for practitioners worldwide. Since 1998, Cutera has been developing innovative, easy-to-use products that harness the power of science and nature to enable medical practitioners to offer safe and effective treatments to their patients. For more information, call +1-415-657-5500 or 1-888-4CUTERA or visit www.cutera.com<\/a>.<\/p>\n

Contacts<\/b> <\/p>\n

\nCutera, Inc.<\/b>
Greg Barker
\n
VP, Corporate FP&A
\n
415-657-5500
\n
IR@cutera.com<\/a><\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

BRISBANE, Calif.–(BUSINESS WIRE)–Cutera, Inc. (Nasdaq: CUTR) (\u201cCutera\u201d or the \u201cCompany\u201d), a leading provider of aesthetic and dermatology solutions, announced today that it received a notice (the \u201cNotice\u201d) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (\u201cNasdaq\u201d) that based on the Company\u2019s April 7, 2023 filing of its Form 10-K for the period … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-55657","6":"format-standard","7":"category-industry"},"yoast_head":"\nCutera Regains Compliance with Nasdaq Listing Rules - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/cutera-regains-compliance-with-nasdaq-listing-rules\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Cutera Regains Compliance with Nasdaq Listing Rules - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"BRISBANE, Calif.–(BUSINESS WIRE)–Cutera, Inc. (Nasdaq: CUTR) (\u201cCutera\u201d or the \u201cCompany\u201d), a leading provider of aesthetic and dermatology solutions, announced today that it received a notice (the \u201cNotice\u201d) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (\u201cNasdaq\u201d) that based on the Company\u2019s April 7, 2023 filing of its Form 10-K for the period ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/cutera-regains-compliance-with-nasdaq-listing-rules\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2023-04-10T22:04:12+00:00\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/cutera-regains-compliance-with-nasdaq-listing-rules\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/cutera-regains-compliance-with-nasdaq-listing-rules\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Cutera Regains Compliance with Nasdaq Listing Rules\",\"datePublished\":\"2023-04-10T22:04:12+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/cutera-regains-compliance-with-nasdaq-listing-rules\\\/\"},\"wordCount\":261,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/cutera-regains-compliance-with-nasdaq-listing-rules\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/cutera-regains-compliance-with-nasdaq-listing-rules\\\/\",\"name\":\"Cutera Regains Compliance with Nasdaq Listing Rules - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"datePublished\":\"2023-04-10T22:04:12+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/cutera-regains-compliance-with-nasdaq-listing-rules\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/cutera-regains-compliance-with-nasdaq-listing-rules\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/cutera-regains-compliance-with-nasdaq-listing-rules\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Cutera Regains Compliance with Nasdaq Listing Rules\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Cutera Regains Compliance with Nasdaq Listing Rules - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/cutera-regains-compliance-with-nasdaq-listing-rules\/","og_locale":"en_US","og_type":"article","og_title":"Cutera Regains Compliance with Nasdaq Listing Rules - Pharma Trend","og_description":"BRISBANE, Calif.–(BUSINESS WIRE)–Cutera, Inc. (Nasdaq: CUTR) (\u201cCutera\u201d or the \u201cCompany\u201d), a leading provider of aesthetic and dermatology solutions, announced today that it received a notice (the \u201cNotice\u201d) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (\u201cNasdaq\u201d) that based on the Company\u2019s April 7, 2023 filing of its Form 10-K for the period ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/cutera-regains-compliance-with-nasdaq-listing-rules\/","og_site_name":"Pharma Trend","article_published_time":"2023-04-10T22:04:12+00:00","author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/cutera-regains-compliance-with-nasdaq-listing-rules\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/cutera-regains-compliance-with-nasdaq-listing-rules\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Cutera Regains Compliance with Nasdaq Listing Rules","datePublished":"2023-04-10T22:04:12+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/cutera-regains-compliance-with-nasdaq-listing-rules\/"},"wordCount":261,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/cutera-regains-compliance-with-nasdaq-listing-rules\/","url":"https:\/\/pharma-trend.com\/en\/cutera-regains-compliance-with-nasdaq-listing-rules\/","name":"Cutera Regains Compliance with Nasdaq Listing Rules - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"datePublished":"2023-04-10T22:04:12+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/cutera-regains-compliance-with-nasdaq-listing-rules\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/cutera-regains-compliance-with-nasdaq-listing-rules\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/cutera-regains-compliance-with-nasdaq-listing-rules\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Cutera Regains Compliance with Nasdaq Listing Rules"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/55657","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=55657"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/55657\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=55657"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=55657"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=55657"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}